Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt‐Koyanagi‐Harada disease
- 7 January 2015
- journal article
- Published by Wiley in Acta Ophthalmologica
- Vol. 93 (6) , e475-80
Abstract
Purpose: To evaluate clinical outcomes of first‐line immunomodulatory therapy (IMT) and prednisone alone or late IMT in Vogt‐Koyanagi‐Harada disease.Methods: Retrospective cohort study of 152 patients with Vogt‐Koyanagi‐Harada disease evaluated in a referral uveitis clinic in Chile from 1985 to 2011. Medical records of these patients were reviewed. Demographic data, clinical evaluation, type of treatment, functional outcomes, glucocorticoid (GC) dose and complications were recorded. Multivariate logistic regression was used to identify prognostic factors of poor response to GC.Results: There were no significant differences between first‐line IMT group and prednisone alone/late IMT group in terms of visual acuity (VA) improvement, complications and GC sparing effect. There was a trend for a higher frequency of systemic adverse effects leading to discontinuation of treatment in patients receiving IMT than in those receiving prednisone (14.6% and 6.5%, respectively). The subgroup of patients with poor response to GC who showed functional improvement had a significantly earlier time to IMT initiation than the patients who had no improvement. We identified following prognostic factors of poor response to GC: VA ≤20/200, fundus depigmentation, chronic disease and tinnitus at diagnosis. Patients with a prognostic factor (excluding tinnitus) and VA improvement had an earlier IMT initiation than those who had worse functional outcome.Conclusion: There were no differences in outcomes between first‐line IMT and prednisone alone/late IMT in the entire VKH group. However, in a subset of patients, there was a significant better functional outcome with earlier IMT initiation.Keywords
This publication has 25 references indexed in Scilit:
- Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroidsActa Ophthalmologica, 2013
- Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt–Koyanagi–Harada diseaseActa Ophthalmologica, 2011
- Comparison of the Clinical Efficacy of Two Different Immunosuppressive Regimens in Patients with Chronic Vogt-Koyanagi-Harada DiseaseOcular Immunology and Inflammation, 2010
- Cyclosporine for Ocular Inflammatory DiseasesOphthalmology, 2010
- Methotrexate for Ocular Inflammatory DiseasesOphthalmology, 2009
- Azathioprine for Ocular Inflammatory DiseasesAmerican Journal of Ophthalmology, 2009
- Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada diseaseEye, 2008
- The Use of Low-Dose Azathioprine in Patients with Vogt-Koyanagi-Harada DiseaseOcular Immunology and Inflammation, 2007
- Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye diseaseBritish Journal of Ophthalmology, 2006
- Vogt-Koyanagi-Harada DiseaseInternational Ophthalmology Clinics, 2005